참고문헌
- Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956;9:822-30. https://doi.org/10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4
- Fajgenbaum DC, Shilling D. Castleman disease pathogenesis. Hematol Oncol Clin North Am 2018;32:11-21. https://doi.org/10.1016/j.hoc.2017.09.002
- Shahidi H, Myers JL, Kvale PA. Castleman's disease. Mayo Clin Proc 1995;70:969-77. https://doi.org/10.4065/70.10.969
- Takenaka K, Takada K, Kobayashi D, Moriguchi M, Harigai M, Miyasaka N. A case of IgG4-related disease with features of Mikulicz's disease, and retroperitoneal fibrosis and lymphadenopathy mimicking Castleman's disease. Mod Rheumatol 2011;21:410-4. https://doi.org/10.3109/s10165-010-0410-7
- Huang H, Feng R, Li J, Song X, Li S, Xu K, et al. Castleman disease-associated diffuse parenchymal lung disease: A STROBEcompliant retrospective observational analysis of 22 cases in a tertiary Chinese hospital. Medicine (Baltimore)2017;96:e8173. https://doi.org/10.1097/MD.0000000000008173
- Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 2017;129:1646-57. https://doi.org/10.1182/blood-2016-10-746933
- Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire JF, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol 2020;72:7-19. https://doi.org/10.1002/art.41120
- Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol 2018;180:206-16. https://doi.org/10.1111/bjh.15019
- Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999;85:706-17. https://doi.org/10.1002/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO;2-7
- Palestro G, Turrini F, Pagano M, Chiusa L. Castleman's disease. Adv Clin Path 1999;3:11-22.
- Vassallo R, Ryu JH, Colby TV, Hartman T, Limper AH. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med 2000;342:1969-78. https://doi.org/10.1056/NEJM200006293422607
- Inoue D, Zen Y, Abo H, Gabata T, Demachi H, Kobayashi T, et al. Immunoglobulin G4-related lung disease: CT findings with pathologic correlations. Radiology 2009;251:260-70. https://doi.org/10.1148/radiol.2511080965
- Mochizuki H, Kato M, Higuchi T, Koyamada R, Arai S, Okada S, et al. Overlap of IgG4-related disease and multicentric Castleman's disease in a patient with skin lesions. Intern Med 2017;56:1095-9. https://doi.org/10.2169/internalmedicine.56.8013
- Sato Y, Kojima M, Takata K, Morito T, Asaoku H, Takeuchi T, et al. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease. Mod Pathol 2009;22:589-99. https://doi.org/10.1038/modpathol.2009.17
- van Rhee F, Voorhees P, Dispenzieri A, Fossa A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 2018;132:2115-24.
- Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003;38:982-4. https://doi.org/10.1007/s00535-003-1175-y
- Yamashita K, Haga H, Kobashi Y, Miyagawa-Hayashino A, Yoshizawa A, Manabe T. Lung involvement in IgG4-related lymphoplasmacytic vasculitis and interstitial fibrosis: report of 3 cases and review of the literature. Am J Surg Pathol 2008;32:1620-6. https://doi.org/10.1097/PAS.0b013e318172622f
- Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, et al. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol 2016;3:e163-75. https://doi.org/10.1016/S2352-3026(16)00006-5
- van Rhee F, Greenway A, Stone K. Treatment of idiopathic Castleman disease. Hematol Oncol Clin North Am 2018;32:89-106. https://doi.org/10.1016/j.hoc.2017.09.008
- van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, et al. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget 2015;6:30408-19. https://doi.org/10.18632/oncotarget.4655